Introduction {#S1}
============

Mammalian SWI/SNF (mSWI/SNF) complexes are ATP-dependent chromatin remodelers that modulate genomic architecture and DNA accessibility, enabling timely and appropriate control of gene expression^[@R1]--[@R11]^. They are combinatorially assembled from the products of 29 total genes into three final-form complexes: canonical BAF, PBAF (polybromo-associated BAF complexes), and a newly-defined non-canonical BAF (ncBAF), with specific subunits specifying distinct complexes, such as PBRM1, ARID2, and BRD7 in PBAF complexes, ARID1A/ARID1B and DPF2 in canonical BAF (cBAF) complexes, and GLTSCR1/GLTSCR1L and BRD9 in ncBAF complexes^[@R12]--[@R15]^. The specific genome-wide targeting and biochemical functions of these distinct complexes to date remain poorly understood, owing in part to limitations in understanding full subunit composition and combinatorial parameters, complex assembly pathways and the paucity of robust strategies to map the relative localization of each complex on chromatin.

Mutations in the genes encoding mSWI/SNF subunits are found in over 20% of human cancers^[@R16],\ [@R17]^, with specific subunits mutated in specific malignancies, pointing toward subunit- and complex-specific functions. For example, \>98% of cases of malignant rhabdoid tumor (MRT) exhibit biallelic loss of the *SMARCB1* gene, which encodes the SMARCB1/BAF47/hSNF5 subunit of BAF and PBAF (but not ncBAF) complexes^[@R18]--[@R20]^. Furthermore, complex-defining subunits such as ARID1A and PBRM1 are recurrently mutated in distinct cancers, ovarian clear cell carcinoma and renal clear cell carcinoma, respectively^[@R21],\ [@R22]^.

While the majority of mSWI/SNF gene mutations result in loss-of-function phenotypes, the SS18-SSX fusion hallmark to synovial sarcoma (SS) results in de novo, gain-of-function targeting of BAF complexes, which activates the unique SS gene expression signature^[@R23]^. Incorporation of the SS18-SSX oncoprotein into BAF complexes results in protein-level destabilization of SMARCB1 (a feature shared with MRT), but this event is secondary and not required for maintenance of SS gene expression or proliferation^[@R23]^. Finally, genetic perturbation screens in cell lines bearing mutations in mSWI/SNF subunits that are part of paralog families (i.e. *SMARCA4* and *ARID1A*) have unveiled synthetic lethal dependencies on residual complexes assembled with their rarely-mutated partner paralogs (i.e. *SMARCA2* and *ARID1B*)^[@R24],\ [@R25]^. Collectively, these findings highlight subunit- and paralog-specific biological roles, such as those demonstrated in the context of development^[@R4],\ [@R8]--[@R10]^.

Defining the functional differences among the diverse array of complexes within the mSWI/SNF family represents a major goal for the field at-large. In this study, we used biochemical and bioinformatic approaches to map mSWI/SNF complexes on chromatin, which revealed an unexpected, complex-specific localization of ncBAF complexes to CTCF and promoter-proximal sites. We find that cancers driven by core cBAF subunit perturbations, such as SS and MRT, are uniquely dependent on ncBAF function. We further demonstrate that perturbation of ncBAF complexes is, unexpectedly, mechanistically distinct from perturbation of synovial sarcoma disease-driver SS18-SSX and that in both SS and MRT settings, ncBAF plays critical roles in maintaining gene expression at retained mSWI/SNF sites.

Distinct function and genome-wide localization across mSWI/SNF complex families {#S2}
-------------------------------------------------------------------------------

Genes involved in similar biological pathways or protein complexes often exhibit coordinated fitness variation ingenetic perturbation screens, such as those performed across hundreds of human cancer cell lines^[@R26]--[@R29]^. Specifically, we have previously established that mSWI/SNF complex genes cluster in to three functional modules: core BAF, PBAF, and an unexpected functional module we termed ncBAF^[@R12]^. Similar analyses performed on a combined shRNA- and CRISPR-Cas9-based dataset (Project Achilles, Broad Institute)^[@R26],\ [@R27],\ [@R30]^ as well as the Project DRIVE (Novartis) dataset^[@R29]^, further suggest that BAF, PBAF, and ncBAF on average represent functionally distinct entities, providing motivation to define their underlying features ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Importantly, in agreement with these functional distinctions, biochemical studies resolved complexes of distinct size and componentry, as demonstrated by complex purifications, mass-spectrometry, and density sedimentation ([Fig. 1b](#F1){ref-type="fig"}--[f](#F1){ref-type="fig"}, [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}--[e](#SD1){ref-type="supplementary-material"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Specifically, we found that ncBAF complexes uniquely lack core, evolutionarily conserved subunits such as SMARCB1 and SMARCE1, incorporate selective paralogs, i.e. SMARCC1 but not SMARCC2 and SMARCD1 but not SMARCD2 or SMARCD3, and contain a set of complex-specific subunits not shared by cBAF or PBAF, the GLTSCR1/1L paralogs and BRD9.

To begin to characterize these distinct assemblies and determine if differential targeting on chromatin may in part underlie their differences, we comprehensively mapped BAF, PBAF, and ncBAF complexes genome-wide by performing ChIP-seq in a mSWI/SNF-intact cell line, EoL-1, using antibodies against pan-mSWI/SNF subunits (SMARCC1 and SMARCA4) and complex-specific subunits BRD9 and GLTSCR1 for ncBAF, DPF2 for canonical BAF (cBAF), and BRD7 for PBAF ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Consistent with biochemical studies, BRD7, DPF2, and BRD9 and GLTSCR1 peaks comprise subsets of all SMARCA4 ATPase subunit peaks, and BRD9 and GLTSCR1 peaks significantly overlap one another ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}--[d](#SD1){ref-type="supplementary-material"}). Hierarchical clustering performed on ChIP-seq read density over the merged set of peaks across all ChIPs performed identified distinct, complex-specific enrichment on chromatin ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}), such as ncBAF complexes over the promoter (green shade), PBAF complex occupancy into the gene body (red shade), and cBAF complexes at distal sites (blue shade) at the *VEGFA* locus ([Fig. 2c](#F2){ref-type="fig"}). ncBAF and PBAF complexes exhibited a distinct promoter-proximal distribution in comparison to cBAF complexes, which were substantially more localized to distal sites ([Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}). Additionally, at transcription start sites (TSSs), PBAF complexes were more enriched over gene bodies relative to ncBAF complexes ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Fig. 2g](#SD1){ref-type="supplementary-material"}).

Motif analyses revealed central enrichment of cBAF complexes over known transcription factor (TF) motifs, including FOS/JUN, AP-1, SPDEF, and ETS (with PBAF complexes enriched at a subset of these), however, ncBAF complexes specifically localized to CTCF sequence motifs, sites well characterized to play roles in the maintenance of DNA architecture^[@R31]--[@R34]^ ([Fig. 2d](#F2){ref-type="fig"}). We performed ChIP-seq for CTCF and indeed found that ncBAF complexes strongly and selectively co-localized with CTCF across cell lines ([Fig. 2e](#F2){ref-type="fig"}, [Supplementary Fig. 2h](#SD1){ref-type="supplementary-material"}). cBAF complexes were most enriched at active enhancers (H3K27ac and H3K4me1) and at primed sites (H3K4me1), suggesting roles for cBAF in enhancer regulation ([Fig. 2f](#F2){ref-type="fig"},[g](#F2){ref-type="fig"}, [Supplementary Fig. 2i](#SD1){ref-type="supplementary-material"}--[k](#SD1){ref-type="supplementary-material"}). In contrast, a greater proportion of PBAF complexes were localized to active promoters (H3K27ac and H3K4me3), at which PBAF complexes were also the most enriched among the three complexes. Finally, ncBAF complexes were most enriched at CTCF sites, particularly CTCF sites co-localized with H3K4me1 ([Supplementary Fig. 2l](#SD1){ref-type="supplementary-material"}). These CTCF co-localized sites comprised a greater portion of all ncBAF peaks relative to cBAF and PBAF peaks. Thus, while the localization and biological roles for mSWI/SNF complexes have been most extensively explored at enhancers^[@R35]--[@R38]^, these results implicate specialized roles for ncBAF and PBAF complexes at CTCF sites and promoters, respectively, and demonstrate mSWI/SNF complex-specific chromatin localization.

Genome-scale fitness screening reveals cancer-specific dependencies on ncBAF complexes {#S3}
--------------------------------------------------------------------------------------

To determine whether ncBAF subunits were uniquely required for proliferative maintenance of any cancer types, analyzed CRISPR-Cas9-based screens performed across 387 cancer cell lines^[@R26]^ and performed screens in 3 new synovial sarcoma (SS) cell lines ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}; Achilles 18Q3 dataset, [https://cds.team/depmap/\#](https://cds.team/depmap/)). These screens identified significant, selective sensitivity of both SS and MRT cell lines to perturbation of ncBAF complex subunits BRD9, GLTSCR1, and SMARCD1 ([Fig. 3a](#F3){ref-type="fig"}). These dependency profiles were specific to SS and MRT, both of which are sarcomas, and not to other soft-tissue malignancies ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). To corroborate these results, we analyzed shRNA-based fitness screens from Project DRIVE^[@R29]^ and again found that SS (n=5) and MRT (n=4) cell lines were selectively sensitive to BRD9 suppression ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). We further confirmed that ncBAF dependency was specific to SS18-SSX fusion oncoprotein-positive SS, as an SS histological mimic cell line, SW982, which lacks the SS18-SSX fusion, was insensitive to ncBAF component perturbation ([Fig. 3c](#F3){ref-type="fig"}).

Both SS and MRT exhibit perturbations to the cBAF core functional module^[@R12]^. SS is uniformly characterized by the t(X;18) chromosomal translocation which produces the SS18-SSX fusion oncoprotein, a stable and dedicated mSWI/SNF complex subunit that destabilizes SMARCB1^[@R39],\ [@R40]^, and MRT and atypical teratoid/rhabdoid tumor (AT/RT) cell lines are driven by biallelic loss of the *SMARCB1* gene (encoding the SMARCB1/BAF47/SNF5/INI1 subunit)^[@R18]--[@R20]^ ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). In SS, loss of proliferative fitness resulting from ncBAF subunit perturbation was comparable to SS18 perturbation, the driver of disease ([Fig. 3a](#F3){ref-type="fig"}). Both SS and MRT cell lines exhibited higher sensitivity to BRD9 loss than AML cell lines, which have been previously been reported to be sensitive to BRD9 knockdown^[@R41],\ [@R42]^ ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). We found that AML cell lines were near uniformly sensitive to depletion of a wide range of mSWI/SNF complex subunits rather than ncBAF components selectively ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). In SS and MRT, SMARCB1 (destabilized and deleted in these cancers) as well as other cBAF and PBAF subunits such as SMARCE1, ARID1A, and BRD7, did not score as dependencies ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig 3c](#SD1){ref-type="supplementary-material"}), highlighting the selective sensitivity to ncBAF subunit disruption in these cancer types.

To validate these findings, we biologically and chemically depleted BRD9 using shRNA and dBRD9 chemical degradation^[@R43]^ strategies. Suppression of BRD9 in SYO-1 synovial sarcoma cells significantly attenuated proliferation, as compared to either control shRNA or shRNA directed against SMARCE1, a structurally essential component of cBAF and PBAF complexes which is not a part of ncBAF, further confirming screening results ([Fig. 3d](#F3){ref-type="fig"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). dBRD9-treated SS cells exhibited near complete depletion of BRD9 from whole cell lysates and proliferative attenuation, approaching that which results from SS18-SSX oncoprotein knockdown ([Fig. 3e](#F3){ref-type="fig"}--[f](#F3){ref-type="fig"}, [Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"},[g](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Knockdown of GLTSCR1 in SYO-1 cells also attenuated proliferation, supporting the role of ncBAF complexes in SS cell maintenance ([Supplementary Fig. 3h](#SD1){ref-type="supplementary-material"}). Cell cycle analysis performed on cells treated with dBRD9 revealed a decrease in cells in S phase and an increase in cells in sub G1 relative to DMSO vehicle control, and Annexin V staining demonstrated an increase in apoptotic cells ([Supplementary Fig. 3i](#SD1){ref-type="supplementary-material"},[j](#SD1){ref-type="supplementary-material"}). Further, global transcriptional profiling revealed similar effects on gene expression between dBRD9 and shBRD9 treatments, while shSMARCE1 resulted in discordant changes and minimal transcriptional effect ([Fig. 3g](#F3){ref-type="fig"}). Finally, dBRD9 treatment of SMARCB1-deficient MRT cell lines TTC1240 and G401 resulted in reduced proliferation ([Fig. 3h](#F3){ref-type="fig"}, [Supplementary Fig. 3k](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}), while treatment in a SMARCB1-intact epithelioid sarcoma (EpS) cell line, ESX, did not ([Supplementary Fig. 3l](#SD1){ref-type="supplementary-material"}). As mSWI/SNF complexes in SS and MRT/ATRT/EpS disease settings exhibit the shared feature of cBAF perturbation and SMARCB1 (BAF47) loss or destabilization, these results unmask a selective ncBAF dependency in two aggressive and intractable BAF-mutant cancer types.

Finally, we compared total degradation of BRD9 (dBRD9 degrader) versus BRD9 bromodomain inhibition using BI-7273. Colony formation assays in SYO-1, HSSYII, and Aska SS cell lines demonstrated that dBRD9 treatment was substantially and reproducibly more potent than BI-7273 (or treatment with lenalidomide control) ([Fig. 3i](#F3){ref-type="fig"}, [Supplementary Fig. 3m](#SD1){ref-type="supplementary-material"},[n](#SD1){ref-type="supplementary-material"}). Moreover, these treatments in cell lines lacking BAF complex perturbations did not result in colony formation inhibition ([Supplementary Fig. 3o](#SD1){ref-type="supplementary-material"}--[q](#SD1){ref-type="supplementary-material"}). Knockout of BRD9 in HEK-293T cells resulted in destabilized ncBAF complexes ([Supplementary Fig. 3r](#SD1){ref-type="supplementary-material"}), perhaps underlying the increased potency of dBRD9 relative to BI-7273. Taken together, these data suggest that total loss of BRD9 is more potent than bromodomain inhibition, supporting the possibility that other domains of BRD9 may be important for BRD9 subunit function.

CRISPR guide RNA tiling experiments define required domains on GLTSCR1 and BRD9 ncBAF subunits {#S4}
----------------------------------------------------------------------------------------------

We next sought to identify specific regions on BRD9 as well as other ncBAF components that uniquely underlie the synthetic lethality in SS. We performed CRISPR tiling screens with an array of guide RNAs against the exonic sequences of several subunits and their paralogs in the SYO-1 synovial sarcoma cell line ([Fig. 4a](#F4){ref-type="fig"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"},[3](#SD1){ref-type="supplementary-material"}). Guides targeting regions of the disease driver, SS18, part of the SS18-SSX fusion, drop out as expected ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"},[b](#SD1){ref-type="supplementary-material"}). Consistent with CRISPR and RNAi screening results above ([Fig. 3](#F3){ref-type="fig"}), cBAF/PBAF-specific subunits SMARCB1 and SMARCE1 did not drop out ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"},[d](#SD1){ref-type="supplementary-material"}), and ncBAF-specific paralogs SMARCD1 and SMARCC1 exhibited more drop out relative to SMARCD2/3 and SMARCC2, respectively, paralogs which do not assemble in to ncBAF ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}--[h](#SD1){ref-type="supplementary-material"}). Interestingly, guides targeting the GLTSCR domain of GLTSCR1 and most of the coding region of BRD9, including the bromodomain and the DUF3512, exhibited significant fitness dropout ([Fig. 4b](#F4){ref-type="fig"},[c](#F4){ref-type="fig"}). In contrast, guides targeting the bromodomain and DUF3512 of PBAF-specific BRD7, the paralog of BRD9, did not result in reduced fitness ([Fig. 4d](#F4){ref-type="fig"}). These data highlight the synthetic lethal specificity for ncBAF components, and demonstrate the importance of the GLTSCR and DUF3512 domains of GLTSCR1/1L and BRD9, respectively, in ncBAF function in SS.

To understand the roles of the GLTSCR and DUF3512 domains in ncBAF complexes, we assessed evolutionary conservation of these regions ([Fig. 4e](#F4){ref-type="fig"},[f](#F4){ref-type="fig"}). The most evolutionarily conserved region of the GLTSCR1/1L paralogs is the GLTSCR domain, suggesting it could possibly serve an important structural role. Indeed, immunoprecipitation followed by immunoblot of N-terminal and C-terminal truncation mutants of mammalian GLTSCR1 demonstrated that this domain is required for interaction with ncBAF complexes and thus serves as an ncBAF-specific binding region ([Fig. 4g](#F4){ref-type="fig"}, [Supplementary Fig. 4i](#SD1){ref-type="supplementary-material"}). In contrast, although the bromodomain and DUF3512 regions are evolutionarily conserved between BRD9 and BRD7 homologs across species ([Fig. 4f](#F4){ref-type="fig"}), mammalian BRD9 and BRD7 paralogs incorporate into ncBAF and PBAF complexes, respectively. To determine if the DUF3512 is involved in complex-specific binding of the BRD9 and BRD7 subunits, we performed domain swapping experiments in which we fused the C-terminal DUF-containing region of BRD9 to the N-terminus of BRD7 and vice versa ([Fig. 4h](#F4){ref-type="fig"}). Swapping of BRD9 and BRD7 DUF3512 regions resulted in switched complex specification, with BRD9-(BRD7 DUF) binding PBAF complexes and BRD7-(BRD9 DUF) binding ncBAF complexes ([Fig. 4h](#F4){ref-type="fig"}). Taken together, these results implicate the BRD9 DUF3512 and the GLTSCR1 GLTSCR domains as ncBAF complex binding domains that underlie critical dependencies in SS cell contexts.

ncBAF is not required for SS18-SSX fusion-mediated gene expression and primarily regulates retained fusion-independent sites {#S5}
----------------------------------------------------------------------------------------------------------------------------

SS18 is a subunit of both cBAF and ncBAF complexes ([Fig. 1](#F1){ref-type="fig"}), and the SS18-SSX fusion protein is a dedicated and stable subunit in cBAF complexes in SS^[@R39]^. To understand the sensitivity of SS cells to ncBAF complex depletion, we examined if SS18-SSX incorporates into ncBAF complexes. Complex purifications via HA-tagged wild-type SS18 and SS18-SSX1 revealed that while ncBAF subunits co-purify with SS18-SSX, they are less robustly captured in the SS18-SSX1 purification than the SS18 purification, relative to SMARCA4 ([Fig. 5a](#F5){ref-type="fig"}).

Since the SS18-SSX1 fusion protein destabilizes SMARCB1, a core subunit in cBAF complexes but not present in ncBAF complexes, we sought to determine whether fusion-containing ncBAF complexes may drive oncogenesis and the hallmark gene expression phenotypes of SS tumors. Thus, we performed RNA-seq on SYO-1 synovial sarcoma cells treated with either an shRNA targeting SS18-SSX (shSSX) or dBRD9. Intriguingly, while treatment with dBRD9 resulted in proliferative attenuation similar to knockdown of disease-driver SS18-SSX ([Fig. 3](#F3){ref-type="fig"}), few genes were concordantly affected by both treatments ([Fig. 5b](#F5){ref-type="fig"}, [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). Specifically, although both BRD9 and SS18-SSX perturbations similarly affected cell cycle pathways consistent with proliferative attenuation, we found discordant effects on mesenchymal stem cell genes, neural differentiation and bivalent polycomb target genes, gene sets hallmark to the SS-specific oncogenic signature, suggesting different underlying mechanisms ([Fig. 5c](#F5){ref-type="fig"})^[@R23],\ [@R39]^.

To determine if BRD9 and hence ncBAF complexes were required for de novo SS18-SSX-mediated gene activation, we performed RNA-seq in CRL7250 human fibroblasts in which we expressed either wild-type V5-SS18 or V5-SS18-SSX1 fusion with or without 24-hour pre-treatment with dBRD9 followed by sustained dBRD9 treatment ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). Despite full degradation of BRD9 protein, dBRD9 treatment did not attenuate SS18-SSX-mediated gene activation and polycomb target genes associated with H3K27me3-mediated repression were equally activated irrespective of dBRD9 treatment ([Fig. 5d](#F5){ref-type="fig"}, [Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}). These data in the SYO-1 and CRL7250 settings suggest that the function of ncBAF complexes is distinct from that of SS18-SSX-bound canonical BAF complexes known to oppose polycomb at cancer-specific sites on the genome^[@R23]^. Additionally, ncBAF is not required for the de novo activation of SS-specific gene signatures driven by the SS18-SSX fusion protein, pointing toward a distinct mechanism underlying ncBAF dependency in synovial sarcoma.

We next sought to define the divergent gene regulatory effects between SS18-SSX1 and BRD9 perturbation. In SS, the SS18-SSX fusion directs targeting of BAF complexes to a cancer-specific set of sites on chromatin which are crucial for oncogenesis^[@R23]^ ([Fig. 5e](#F5){ref-type="fig"}). To assess whether the SS18-SSX fusion hijacks BRD9 to such cancer-specific sites, we performed ChIP-seq for BRD9 before and after SS18-SSX knockdown and found that BRD9 is minimally retargeted by the SS18-SSX fusion to broad-peak fusion-dependent sites ([Fig. 5e](#F5){ref-type="fig"}). However, fusion-independent sites (sites retained irrespective of SS18-SSX knockdown) are largely marked by H3K4me3 and CTCF ([Fig. 5e](#F5){ref-type="fig"}), two hallmarks of ncBAF complex targeting ([Fig. 2](#F2){ref-type="fig"}), whereas fusion-dependent sites are not.

We found that genes closest to fusion-dependent sites were strongly downregulated by SS18-SSX knockdown^[@R23]^, but expression of these genes did not change with BRD9 degradation ([Fig. 5f](#F5){ref-type="fig"}, [Supplementary Fig. 5d](#SD1){ref-type="supplementary-material"}). Instead, the most downregulated genes upon dBRD9 treatment were closest to fusion-independent sites ([Fig. 5g](#F5){ref-type="fig"}, [Supplementary Fig. 5e](#SD1){ref-type="supplementary-material"}). This result is consistent with the lack of requirement for BRD9 in mediating de novo activation of fusion-dependent genes in CRL7250 fibroblasts and the divergent transcriptional effects between shSS18-SSX and dBRD9 treatments in SYO-1 SS cells. Finally, we compared changes in gene expression upon dBRD9 treatment with gene dependency scores derived from CRISPR screening, and found that genes downregulated by dBRD9 treatment significantly enriched for sensitivities ([Fig. 5h](#F5){ref-type="fig"}). However, dBRD9 treatment in a BAF-intact cancer cell line, such as MOLM-13, did not result in preferential downregulation of genes that are enriched for dependencies ([Supplementary Fig. 5f](#SD1){ref-type="supplementary-material"}). Taken together, these results support a model in which BRD9/ncBAF complexes are important for regulation of gene expression at fusion-independent sites. We propose that ncBAF complexes, which preferentially associate with wild-type SS18 and are, in contrast to canonical BAF complexes, less perturbed by the incorporation of the fusion protein, are critical for maintenance of essential genes at fusion-independent sites in a setting in which SS18-SSX has further targeted canonical BAF complexes away from these sites.

ncBAF is required for the maintenance of gene expression via retained co-localization with CTCF in SMARCB1-deficient cancers {#S6}
----------------------------------------------------------------------------------------------------------------------------

In the absence of SMARCB1 in MRT cell lines, residual SMARCA4-marked mSWI/SNF complexes are substantially more localized to promoter-proximal sites and are deficient in enhancer targeting^[@R37],\ [@R38]^. Previous studies using *Brg1 (Smarca4)* conditional KO in mouse models identified that Smarcb1-deficient cells are still dependent on Smarca4 for survival^[@R44]^, and these data have been more recently corroborated in large-scale dependency screens in cancer cell lines. Thus, we asked whether these residual mSWI/SNF complexes in MRT would primarily represent intact ncBAF complexes. We performed ChIP-seq for BRD9 in MRT cell line TTC1240, finding that BRD9 localizes to a large proportion of SMARCA4 sites ([Fig. 6a](#F6){ref-type="fig"}). In contrast, ncBAF complexes co-localize with approximately 1/3 or fewer of all SMARCA4 sites in mSWI/SNF- intact settings, such as MOLM13 and Jurkat cells, and in MRT TTC1240 cells in which SMARCB1 has been rescued ([Fig. 6b](#F6){ref-type="fig"}). Thus, a large percentage of residual mSWI/SNF complexes required for proliferative maintenance in SMARCB1-deficient cell lines represent ncBAF complexes.

BAF complex localization and function at enhancers and superenhancers (SEs) have been shown to be aberrant in MRT^[@R37],\ [@R38]^. We examined BRD9 targeting to MRT-specific SEs, defined by Chun et al. in primary tumors and cell lines compared to hESC lines and fetal brain tissue^[@R45]^. The TTC1240 cell line exhibits strong overlap with these primary tumor-associated MRT-specific enhancers and SEs ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}) and BRD9-marked ncBAF complexes localized to a large number of these MRT-specific SEs, particularly those which encompass a TSS ([Fig. 6c](#F6){ref-type="fig"}). To investigate the role for BRD9 at these genes in MRT, we treated TTC1240 cells with dBRD9 and performed ChIP-seq and RNA-seq. Treatment with dBRD9 resulted in a significant decrease in SMARCA4 occupancy, particularly, at BRD9-marked sites genome-wide ([Fig. 6d](#F6){ref-type="fig"}--[f](#F6){ref-type="fig"}, [Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). Consistent with overlap at SEs, lost SMARCA4 peaks were highly enriched in H3K27Ac relative to peaks that did not change ([Fig. 6g](#F6){ref-type="fig"}). Additionally, many downregulated genes had BRD9 occupancy at their promoters and significantly changing genes had higher H3K27Ac and BRD9 occupancy than non-significantly changing active genes ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). Genes that were downregulated by dBRD9 and lost SMARCA4 occupancy were enriched for those genes overexpressed in MRT compared to wild-type tissue or defined as regulated by MRT-specific super enhancers (i.e. *JUND*, *VGF*, *ID3*, *HOXC9*, and *CREB3L1*) ([Fig. 6h](#F6){ref-type="fig"})^[@R45]^ and involved in development and differentiation ([Supplementary Fig. 6d](#SD1){ref-type="supplementary-material"}). Finally, loss of SMARCA4 occupancy was specific to the MRT cell setting, as dBRD9 treatment in MOLM13, a BAF-intact cell line, did not result in similar loss of SMARCA4 ([Fig. 6i](#F6){ref-type="fig"}). Similar to SS, these data support a model in which ncBAF complexes, the only mSWI/SNF family complexes not perturbed by SMARCB1 loss, are critical for gene expression maintenance and subsequently the proliferative capacity, of MRT cells.

Since SS and MRT, which share in common core cBAF (particularly SMARCB1) perturbation, are dependent on ncBAF complexes that regulate gene expression at retained mSWI/SNF sites, we investigated if there were any convergent features between these sites in these two distinct disease settings. Importantly, we found that SMARCA4-marked mSWI/SNF complexes in MRT and SS both converge on a largely promoter-proximal and CTCF co-localized distribution, two hallmarks of ncBAF complex localization ([Fig. 2](#F2){ref-type="fig"}), relative to SMARCA4 in mSWI/SNF-intact cell types ([Fig. 6j](#F6){ref-type="fig"}, [Supplementary Fig. 6e](#SD1){ref-type="supplementary-material"},[f](#SD1){ref-type="supplementary-material"}). In both SS and MRT cell lines, enrichment of BRD9 at CTCF sites remained unchanged upon SS18-SSX knockdown or SMARCB1 re-introduction, respectively, further highlighting that default, hallmark ncBAF complex-specific targeting to promoters and CTCF sites occurs irrespective of BAF complex perturbations ([Fig. 6k](#F6){ref-type="fig"}, [Supplementary Fig. 6g](#SD1){ref-type="supplementary-material"},[h](#SD1){ref-type="supplementary-material"} ).

These data support in a model in which ncBAF complexes maintain gene expression at retained, promoter-proximal and CTCF sites when regulatory functions of the core cBAF functional module containing SMARCB1, SMARCE1, and ARID1A/B are perturbed ([Fig. 6l](#F6){ref-type="fig"}). ncBAF complex disruption (chemical or biological)leads to a loss of gene expression maintenance, defining the cancer-specific sensitivities of cBAF-deficient cancers such as SS and MRT ([Fig. 6m](#F6){ref-type="fig"}).

Discussion {#S7}
==========

In this study, we generated comprehensive chromatin binding profiles for all three mSWI/SNF family complexes relative to defined genomic features. Occupancy patterns of ncBAF, BAF, and PBAF complexes to CTCF sites, active enhancers, and active promoters, may in part underlie complex-specific functional roles implicated in cell fitness screening efforts. These mSWI/SNF localization studies provide an important platform upon which to identify specific complex-chromatin interaction mechanisms governing preferential genome-wide targeting profiles. Differences in histone binding affinities, interactions with general or tissue-specific transcription factors, or complex-specific steric constraints for binding chromatin landscape features are likely at play, alone and in combination, to direct targeting.

Importantly, we identify a synthetic lethal relationship in specific cancers with perturbations to the core cBAF functional module: synovial sarcoma (driven by the SS18-SSX fusion) and SMARCB1-deficient malignant rhabdoid tumor. These cancers are uniquely and specifically dependent on ncBAF complexes for proliferative maintenance, unveiling ncBAF as a potential target for therapeutic intervention in these cancers (relative to other cancer types spanning hundreds of other lineages). Our findings are particularly exciting given recent development of selective small molecule inhibitors and chemical degraders targeting BRD9 ^[@R41]--[@R43],\ [@R46]^. Further studies will be needed to carefully define in vivo properties of these compounds. Our identification of domains within ncBAF-specific subunits that underlie these dependencies, such as the GLTSCR domain of GLTSCR1/1L and the DUF3512 of BRD9, further expands therapeutic opportunities.

In characterizing the convergent mechanism of ncBAF dependency in synovial sarcoma and malignant rhabdoid tumor, unexpectedly, we found that although ncBAF complexes do incorporate the SS18-SSX fusion that drives synovial sarcoma, perturbation of BRD9 and disruption of SS18-SSX are mechanistically distinct. ncBAF complexes primarily regulate retained fusion-independent sites, linking to SMARCB1-deficient MRT in which ncBAF complexes comprise a large share of essential residual complexes that likewise maintain gene expression at retained mSWI/SNF sites. The retained sites in both of these disease settings share in common CTCF co-localization and promoter proximity, the two hallmarks of ncBAF complex localization. Thus, this work now provides a complex-specific basis for previously identified dependencies on SMARCA4 (BRG1) in SMARCB1-deficient cancers^[@R44]^, and highlights the importance of understanding subunit-specific contributions to complex assembly and function when designing strategies to target mSWI/SNF-perturbed cancers. Excitingly, our data suggest the possibility that other cBAF-perturbed cancers, such as those with loss of ARID1A/B or SMARCE1^[@R47],\ [@R48]^, may exhibit similar ncBAF dependencies.

Materials and Methods {#S8}
=====================

Cell lines and tissue culture {#S9}
-----------------------------

HEK-293T, G401, TTC1240, ESX, IMR-90, BJ Fibroblast, CRL7250, and NCIH-1437 cells were grown in DMEM (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco), and 1% penicillin-streptomycin (Gibco). ES-2 cells were grown in McCoy's 5A (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco), and 1% penicillin-streptomycin (Gibco). EoL-1 and MOLM-13 were grown in RPMI (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco), and 1% penicillin-streptomycin (Gibco). RD were cultured in DMEM (Gibco) supplemented with 10% FBS. HCT116 were grown in McCoy's 5A (Gibco) supplemented with 10% FBS. Calu-6 were grown in EMEM (ATCC 30--2003) supplemented with 10% FBS. SYO-1 was grown in DMEM without sodium pyruvate (Gibco) supplemented with 10% FBS, 1% GlutaMAX (Gibco), and 1% penicillin-streptomycin (Gibco). The SYO-1 cell line was a gift from Akira Kawai (National Cancer Center Hospital, Japan. ASKA and HS-SY-II cell lines were obtained from RIKEN^[@R49]^. The CRL7250 human fibroblast cell line was a kind gift from Drs. Berkeley Gryder and Javed Khan (National Cancer Institute, Bethesda, MD).

Constructs and cloning {#S10}
----------------------

Lentiviral shRNA hairpins targeting BRD9 (RHS4430--200302441), SMARCE1 (RHS4430--200219172), and a non-silencing control (RHS4346) were constitutively expressed from the pGIPZ vector and obtained from GE Dharmacon; hairpins targeting GLTSCR1 were inducibly expressed from the pTRIPZ vector (\#RHS4696) from GE Dharmacon.

shRNA hairpins targeting SS18-SSX (5'-CAGTCACTGACAGTTAATAAA-3') or a non-targeting scramble control (5'-CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3') were constitutively expressed from the pLKO.1 vector with puromycin selection.

All expression constructs were cloned using In-Fusion HD (cat. 639650) per manufacturer's recommendations. V5-GLTSCR1 and corresponding N-Del and C-Del mutants were synthesized and cloned into a modified pTight vector by GenScript Biotech Corporation. GLTSCR1L (clone 40146333) was cloned with a V5 tag into a modified pTight vector using In-Fusion HD. HA tag sequence was included in the primers for human BRD9, BRD7, SMARCD1, DPF2, and GLTSCR1L and cloned into a modified pTight vector under constitutive EF1alpha-driven expression with a blasticidin resistance gene. HA-BRD9(B7C) contains amino acids 1--265 of BRD9 and amino acids 266--651 of BRD7. HA-BRD7(B9C) contains amino acids 1--265 of BRD7 and amino acids 266--597 of BRD9. HA-BRD9(B7C) and HA-BRD7(B9C) were cloned in steps, with the N- and C-terminal fragments amplified independently, followed by mixing N- and C-terminal PCR products in equal quantities in a subsequent PCR reaction to fuse the two fragments together, into the same modified pTight vector with a puromycin resistance gene. All primers used for cloning are listed in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}.

Lentiviral Production and Transduction {#S11}
--------------------------------------

shRNA or gene delivery vectors, psPAX2, and pMD2.g were transfected into HEK-293T cells at a ratio of 4:3:1 using PEI (Polysciences, Inc.). Media was filtered through 0.4micron filters 72h post transfection and lentiviral particles were concentrated at 20,000rpm for 2.5h at 4°C. Lentiviral particles were resuspended in 200μl PBS and cells were transduced using 1:1000 polybrene (Santa Cruz Biotechnology, cat. sc-134220). Two days post-infection, cells were selected with 2μg/mL puromycin or 10μg/mL blasticidin.

Proliferation Curves {#S12}
--------------------

25,000--40,000 cells were plated per well of 12 well plates, or 50,000--60,000 per 10cm plate, depending on cell line. Cell counts were performed in biological triplicate using a Vi-CELL XR Cell Counter (Beckman Coulter) on days indicated.

Colony Formation Assays {#S13}
-----------------------

Colony formation assays were performed in 6-well or 12-well format. For each cell line, appropriate cell seeding conditions were first identified in a 14-day assay format. A titration of cell number of each of the cell lines was performed to identify the best cell seeding condition. Compounds were treated continuously for 14 days at the indicated concentration, with change of medium every 5 days. By day 14, medium was removed, and cells were washed with PBS and stained using 500uL of 0.005% (w/v) crystal violet solution in 25% (v/v) methanol for at least 1 hour at room temperature.

Cell Cycle Analysis {#S14}
-------------------

Cell cycle analysis was performed using the Click-iT™Plus EdU Flow Cytometry Assay (Invitrogen). Apoptosis assay was performed using the Annexin V-FITC Apoptosis Detection Kit (Sigma A9210). Assays were performed according to the manufacturer's protocol. SYO-1 cells were treated for 8 days and compound was refreshed every 5 days.

CRISPR Domain Scanning {#S15}
----------------------

To perform high density sgRNA tiling screen, sgRNA library against BAF complex subunits were custom synthesized at Cellecta (Mountain View, CA) following Cellecta's recommendation. Negative and positive control sgRNA were included in the library for quality control check with the screening results. Negative controls consist of 200sgRNAs that do not target human genome. The positive controls are sgRNAs targeting essential genes (CDC16, GTF2B, HSPA5, HSPA9, PAFAH1B1, PCNA, POLR2L, RPL9 and SF3A3). All positive and negative control sgRNA are listed in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Procedure for virus production, cell infection and performing sgRNA screen were previously described ^[@R26],\ [@R50]^. For each sgRNA, 50 counts were added to the sequencing counts and the resulting counts were normalized to the total number of counts. The log2 of the ratio between the counts (defined as dropout ratio) at day 24 and day 1 post-infection was calculated ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). For negative control sgRNAs the 2.5 and 97.5 percentile of the log2 dropout ratio of all non-targeting sgRNAs was calculated and considered as background (grey box in the graph). Protein domains were obtained from PFAM regions defined for the following UNIPROT identifiers: BRD9 : Q9H8M2, BICRA : Q9NZM4, BRD7 : Q9NPI1, SMARCA2 : P51531, SMARCA4 : Q9HBD4, SMARCB1 : G5E975, SMARCC1 : Q92922, SMARCC2 : Q8TAQ2, SMARCD1 : Q96GM5, SMARCD2 : Q92925, SMARCE1 : Q969G3, SS18 : Q15532, SSX2 : Q16385. Rolling averages were calculated for each nucleotide in the corresponding transcript by selecting a 150 nucleotide window centered at the corresponding position and calculating the average of log2 dropout ratio of the sgRNAs in the window.

mSWI/SNF Complex Purification {#S16}
-----------------------------

Mammalian SWI/SNF complexes were purified as previously described ^[@R51]^. In this study, complexes were purified from HEK-293T cells stably expressing HA-tagged constructs (as indicated). Cells were scraped from plates and washed with cold PBS. Suspension was centrifuged at 3000 rpm for 5 min at 4°C and pellets were resuspended in hypotonic buffer (HB) containing 10mM Tris HCl pH 7.5, 10mM KCl, 1.5 mM MgCl~2~, 1mM DTT, 1mM PMSF and incubated on ice for 5min. Suspension was centrifuged at 5000 rpm for 5 min at 4°C, and pellets were resuspended in 5 volumes of fresh HB containing protease inhibitor cocktail and homogenized using glass Dounce homogenizer. Suspension was layered onto HB sucrose cushion containing 30% sucrose w/v, centrifuged at 5000 rpm for 1 hour at 4°C and cytosol-containing layer was discarded. Nuclear pellets were resuspended in high salt buffer (HSB) containing 50mM Tris HCl pH 7.5, 300mM KCl, 1mM MgCl~2~, 1mM EDTA, 1mM, 1% NP40, 1mM DTT, 1mM PMSF and protease inhibitor cocktail. Homogenate was incubated on rotator for 1H. Homogenates then were centrifuged at 20,000 rpm (30,000 x g) for 1 hour at 4°C using an SW32Ti rotor. Chromatin pellets were discarded and high salt nuclear extract was filtered through a 0.45μm filter and incubated overnight with HA magnetic resin. HA beads were washed in HSB and eluted with HSB containing 1mg/ml of HA peptide for 4 times 1.5 hour each. Eluted proteins were then subjected to density gradient centrifugation or dialysis.

Protein Extraction Methods {#S17}
--------------------------

Ammonium sulfate nuclear extraction was performed as described previously^[@R38]^. Pellets were resuspended in IP buffer (300 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA and 1% Triton-X100 with protease inhibitor, 1 mM DTT and 1 mM PMSF) for subsequent experiments.

For whole cell lysates, cells were washed in PBS and resuspended in \~5 volumes of extraction buffer (20mM Tris and 1.5% SDS). Chromatin was solubilized via sonication, and proteins were quantified using BCA.

Immunoprecipitation {#S18}
-------------------

Nuclear extracts were quantified using BCA, and 1mg of protein at 1mg/mL in IP buffer supplemented with protease inhibitors was used per IP with 2--5ug of antibody or with 25uL of Pierce Anti-HA Magnetic Beads (cat. 88837) overnight with rotation at 4°C. Nuclear extract + antibody solution was incubated with 30uL of Protein G Dynabeads (Thermo Fisher) for 2h at 4°C with rotation and washed 5 times with IP buffer. Immunoprecipitated proteins were eluted with sample buffer (2X NuPAGE LDS buffer with 100mM DTT) and loaded onto 4--12% Bis-Tris NuPAGE Gels (Life Technologies). See **Reporting Summary** for antibodies used in this study.

Glycerol Gradient {#S19}
-----------------

Linear 10--30% glycerol gradients were prepared in 14 x 89mm polyallomer centrifuge tubes (Beckman Coulter, cat. 331327) by overlaying 10% glycerol solution in HEMG buffer on 30% glycerol solution with mixing by a Gradient Master. 500--1000ug of nuclear extracts were resuspended in 200μL 0% glycerol HEMG and overlaid on the gradient. Purified protein complexes were loaded in their elution buffers. Gradients were centrifuged in an SW41 rotor at 40,000rpm for 16h at 4°C, and 0.55mL fractions were collected for analysis.

Mass Spectrometry Sample Preparation and Analysis {#S20}
-------------------------------------------------

Purified complex elutions (BRD9, BRD7, Mock) or glycerol gradient fractions (DPF2, fractions 13--14) were concentrated using StrataClean beads, loaded onto 4--12% SDS PAGE gels, migrated 2cm into the gel, and stained with colloidal blue (Invitrogen). Stained samples were excised and sent to Taplin Biological Mass Spectrometry Facility at Harvard Medical School for analysis. Heatmap displaying log2(number of total peptides+1) was created using Seaborn.

Protein SDS PAGE {#S21}
----------------

Proteins were run on 4--12% Bis-Tris NuPAGE gels (Life Technologies). For Western blot, proteins were wet transferred onto PVDF membranes at 300mA for 2.5h, blocked for 1h with 10% milk PBS-T, and visualized using LI-COR Odyssey CLx. For silver stain, gels were stained using SilverQuest Silver Staining Kit (Thermo Fisher) according to manufacturer's protocol.

Chromatin Immunoprecipitation (ChIP) {#S22}
------------------------------------

Cells were fixed in 1% formaldehyde (Sigma Aldrich, F8775) for 10min at 37°C and quenched with 125mM glycine for 5min at 37°C. Cells were subsequently washed with cold PBS and stored at -80°C until use. 10M cells per ChIP were used for EoL-1, MOLM-13, and Jurkat cell lines, and 5M cells per ChIP were used for SYO-1 and TTC1240 cell lines. Nuclei were extracted and chromatin was sonicated using the adaptive focused acoustics technology with a Covaris sonicator. Sonicated chromatin was used in immunoprecipitation reactions with indicated antibodies (**see Reporting Summary**) overnight followed by capture using Protein G Dynabeads (Thermo Fisher). For ChIP-seq using spike-in chromatin, 15ng of spike-in Drosophila chromatin (Active Motif, cat\#530830) was added to each sample with 2ug of spike-in antibody (Active Motif, cat\#61686). Captured antibody-chromatin complexes were washed, eluted, and treated with RNAse A (Roche 11 119 915 011) for 30min at 37°C and Proteinase K (Life Technologies 100005393) for 3 hours at 65°C. ChIP DNA was extracted using SPRI beads (Beckman Coulter Agencourt AMP Xpure), washed, and eluted.

RNA-seq Sample Preparation {#S23}
--------------------------

RNA was collected from 2 million cells per condition, in biological duplicate, using the RNeasy Mini Kit (QIAGEN) according to manufacturer's protocol.

Library Preparation and Sequencing {#S24}
----------------------------------

Library preparation and sequencing of ChIP DNA and RNA was performed by the Molecular Biology Core Facilities at the Dana-Farber Cancer Institute (75bp single end on Illuminia Nextseq 500).

ChIP-Seq Data Alignment {#S25}
-----------------------

For alignment of ChIP-seq data, Bowtie2, version 2.1.0^[@R52]^ was used to map reads to the hg19 human reference genome, using the parameter --k 1.

For spike-in normalization, Drosophila DNA was aligned to the dm3 genome using Bowtie2 version 2.1.0 with the parameter --k 1. Duplicated reads were removed using samtools rmdup with the --b option. (SAMtools v1.3.1) As per manufacturer instructions, normalization ratios were calculated using the ratio of the total number of non-redundant mapped reads in each sample in comparison to the sample with the fewest non-redunant mapped reads.

ChIP-Seq Data Analysis {#S26}
----------------------

### Data processing {#S27}

MACS2^[@R53]^ version 2.1.0 was used to call peaks against input with a cutoff of q=.001. In EoL-1, MOLM-13 and TTC1240 narrow peaks were called for all SWI/SNF antibodies and CTCF while broad peaks were used for all histone marks. In SYO-1, broad peaks were called for all antibodies. Peaks that fell in ENCODE blacklisted regions or were mapped to unmappable chromosomes (not chr1--22, X or Y) were removed. Quality control metrics are available in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}. All down stream analysis was performed on bam files with duplicates removed using the samtools rmdup command with the --b option. ChIP-seq tracks were generated using the bedGraphToBigWig script downloaded from UCSC. Bedgraph files were generated with MACS2 using the --B --SPMR options. For TTC1240 SMARCA4 tracks shown, the bedGraph file values were multiplied by the spike-in normalization ratios calculated as described above.

Overlaps for ChIP venn diagrams were created using the ChIPPeakAnno^[@R54]^ v3.10.1 bioconductor package, peak files were read in using the toGRanges() command, values were determined using the getVennCounts() function with maxgap=0. Data was visualized using matplotlib. The number of overlapping peaks displayed in pie charts, bar charts and heatmaps was determined using the pybedtools^[@R55]^ intersect function. Proportions were calculated by dividing the number of overlapping peaks by the number of total peaks.

Read count across peak sets of interest were calculated by calling the Rsubread^[@R56]^ v1.26.1 bioconductor package function featureCounts() on duplicate removed bam files. These values were divided by the total number of mapped reads divided by one million, giving a normalized value of reads per million mapped reads for each interval in the input bed.

Peak distance from TSS elements was determined using BEDtools v2.26.0 closest function with the hg19 ref Flat TSS annotation.

Determination of super enhancers was performed using ROSE^[@R57],\ [@R58]^ with all default settings using the TTC1240 H3K27ac ChIP-seq file and TTC1240 H3K27ac peak file as input. MRT-specific super enhancers were downloaded from Chun et al^[@R45]^ and merged using bedtools merge, as many of their published enhancers abutted one another.

### Data analysis and visualization {#S28}

Metagene plots and heatmaps were generated created using HTSeq^[@R59]^ v0.9.1. To account for the 200bp average fragment length selected for in sonication, fragment length was extended 200 bp from the edge of each genomic interval. Total read counts for each interval were normalized to reads per million mapped reads (RPM). For each antibody the resulting matrix has a width of the number of bp in the window (in this study primarily 5000) and a height of the number of peaks in the indicated set. Strandedness of the interval was not considered, except for the TSS metagene plot in [Supplementary Figure 2g](#SD1){ref-type="supplementary-material"}. Metagene plots show the average RPM at each position. Heatmaps were visualized using python. Heatmaps were ordered by the maximum value in each matrix row of the indicated antibody. Heatmaps were colored such that the midpoint of the color spectrum is equivalent to the median of the set of maximum values in each row. For heatmaps where multiple peak sets are shown, these color values were calculated for each antibody across both sets together. For the spike-in normalized heatmap, all heatmap data was calculated as described but then multiplied by the normalization factor, described above, before plotting.

The EoL-1 histone mark and CTCF heatmap in [Supplementary Fig. 2i](#SD1){ref-type="supplementary-material"} the HTSEQ procedure described above was carried over peaks that had been split into 100 bins and 2500 bp on either side of the peak. The resulting matrix was k-means clustered to 4 clusters. This was carried out over the merged set of all EoL-1 mSWI/SNF peaks.

The SYO-1 differential heatmap ([Fig. 5e](#F5){ref-type="fig"}) was ordered by the ratio of the row means for BRD9 in the +/- shSSX conditions. Any interval that had more than or equal to a 25% increase in mean BRD9 ChIP occupancy upon shSSX treatment was considered gained. Any interval that had more than or equal to 25% decrease in mean BRD9 ChIP occupancy upon shSSX treatment was considered lost. Intervals that did not change more than 25% in either direction were considered retained.

Differential occupancy of SMARCA4 in TTC1240 upon dBRD9 treatment was determined using the DiffBind v2.4.8 bioconductor package (<https://bioconductor.org/packages/release/bioc/html/DiffBind.html> ), with all default settings. Peak files and duplicate removed bam files were provided for each SMARCA4 sample in each condition, along with the bam files corresponding to the input in each condition. The package functions count(), contrast(), analyze(), and report() were used in sequence.

Gene ontology of genes near lost SMARCA4 sites in TTC1240 ([Fig. S6d](#SD1){ref-type="supplementary-material"}) was performed using Genomic Regions Enrichment of Annotations Tool (GREAT)^[@R60]^.

### Motif Analysis {#S29}

A fasta sequence for a region of 250 bp on either side of the center of each peak was generated using the bedtools getfasta function. Motif analysis on these sequences was done was done using the MEME-ChIP suite^[@R61]^.

In [Fig. 2d](#F2){ref-type="fig"}, for each antibody the motif with the highest CentriMo log-adjusted p-value in the indicated TF Family was selected. These log-adjusted p-values were used to make a heatmap using the Seaborns clustermap function, clustered by correlation.

Enrichment plots for the motifs are the average number of the CentriMo site counts for each antibody in the window around the indicated motif split into bins of 10 bp.

RNA-Seq Data Analysis {#S30}
---------------------

### Data processing {#S31}

RNA-seq data reads were mapped using default parameters to hg19 using STAR^[@R62]^ version 2.5.2a.

RPKM values were calculated using GFOLD version 1.1.4^[@R63]^. Unless otherwise noted, log2 fold change and Bonferri-corrected p values were generated using DESEQ2 v1.16.1, with reads mapped using RSUBREAD^[@R56]^ v1.26.1. Genes were considered significantly changing if they had an adjusted p-value \<.001 and a log2 fold change of at least .59 (approximately 50% change). All RNA-seq experiments were performed in biological replicate. Quality control metrics are available in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}.

RNA BigWig files were generated using the bamCoverage command from deepTools release 2.4^[@R64]^ with all default settings.

### Data analysis/visualization {#S32}

The input for Gene Set Enrichment Analysis (GSEA)^[@R65]^ was created by calculating the log2 fold change between the mean RPKM of the replicates in each condition +1. Noncoding genes (SNO and MIR RNA's) were excluded, as were genes that did not have an expression level of at least 1 RPKM in any condition of the comparison. GSEA Preranked was run over these files with default settings.

Gene ontology and pathway terms of gene clusters in Synovial Sarcoma ([Fig. S5a](#SD1){ref-type="supplementary-material"}) were determined using Metascape^[@R66]^.

Genes associated with MRT superenhancers were downloaded from Chun et al.^[@R45]^. Differential expression files of genes between MRT and normal tissues were downloaded from Chun et al., genes that were overexpressed in MRT with Bonferroni-adjusted p-value \< .01 were considered overexpressed in MRT.

CRISPR-Cas9 and shRNA synthetic lethal screening data analysis {#S33}
--------------------------------------------------------------

DRIVE data is publicly available and downloaded from the Novartis DRIVE Data Portal^[@R28]^. Statistical analysis was performed using the scipy.stats package.

Significance values for shBRD9 in tissue types were calculated using a Fisher's Exact Test, and FDR corrected using the Benjamini-Hochberg procedure. An ATARIS score of -.75 was used as the cutoff for sensitivity.

### Principal components analysis of fitness data from Project Achilles {#S34}

Datasets were obtained from the Project Achilles Data Portal (<https://portals.broadinstitute.org/achilles/about> ). The CRISPR data (Avana-18Q1) and the RNAi data (2.20.2) for BAF subunits were scaled across cell lines. In the RNAi dataset, cell lines were omitted if fitness scores were not available for all BAF genes. The fitness scores from both datasets were concatenated and correlated across genes, and principal components analysis was performed on the resulting correlation matrix (R prcomp, default settings). The first two principle components were plotted.

All heatmaps and plots were generated using matplotlib and/or seaborns. Unless otherwise noted, all default parameters were used for the seaborn clustermap function.

Code Availability Statement {#S35}
---------------------------

Code used in this paper is available from the corresponding author upon request.

Data Availability Statement {#S36}
---------------------------

The ChIP-seq and RNA-seq data sets generated and/or analyzed during the current study have been deposited in the Gene Expression Omnibus (GEO) repository under accession number **GSE113042** (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113042>).

Other data sets that were previously published and used in this study have been deposited in the Gene Expression Omnibus (GEO) repository under accession numbers GSE90634 and GSE108025 available at (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90634> ) and (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108025> ) respectively.The fitness data were derived from Project Achilles through the Project Achilles Data Portal (<https://portals.broadinstitute.org/achilles/about> ). The data-set derived from this resource that supports the findings of this study is available at <https://portals.broadinstitute.org/achilles/datasets/all>. The fitness data were also derived from Project DRIVE. The data-set derived from this resource that supports the findings of this study is available at <https://oncologynibr.shinyapps.io/drive/>.

All proteomics/ mass-spectrometry data is deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011103.

Statistics and Reproducibility {#S37}
------------------------------

All statistics performed on data in this manuscript are detailed above, and statistical tests and their parameters used are indicated in the legends. Representative data are shown from independently repeated experiments with similar results.
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![mSWI/SNF family complexes are biochemically and functionally distinct.\
a. Principal component analysis (PCA) performed on fitness correlations between mSWI/SNF genes from combined genome-scale RNAi- and CRISPR-Cas9-based genetic perturbation screens (Project Achilles, Broad Institute).\
b. SDS-PAGE and silver stain performed on purified complexes using indicated HA-tagged subunits expressed in HEK-293T cells. Purifications performed in n=3 biologically independent experiments for each bait.\
c. Proteomic mass-spectrometry performed on mSWI/SNF complexes purified from HEK-293T cells expressing indicated HA-tagged mSWI/SNF subunits.\
d. Immunoprecipitation for endogenous SMARCA4 (pan-mSWI/SNF complex component), ARID1A (canonical BAF-specific), BRD7 (PBAF-specific), and BRD9 (ncBAF-specific) subunits in HEK-293T nuclear extracts followed by immunoblot for select subunits. Subunits in blue, red, and green represent BAF-, PBAF-, and BRD9/GLTSCR1- specific complexes, respectively. Immunoprecipitations performed in n=2 biologically independent experiments. See also [Supplementary Figure 7a](#SD1){ref-type="supplementary-material"}.\
e. Separation of HEK-293T nuclear extracts via 10--30% glycerol gradient density sedimentation followed by immunoblot for selected mSWI/SNF subunits. Glycerol gradient performed in n=3 biologically independent experiments. See also [Supplementary Figure 7b](#SD1){ref-type="supplementary-material"}.\
f. Schematic depicting biochemical subunit compositions for mammalian ncBAF, canonical BAF, and PBAF complexes.](nihms-1507828-f0001){#F1}

![Differential localization of mSWI/SNF complexes, ncBAF, cBAF, and PBAF, on chromatin.\
a. Venn diagram of peaks from BRD9, GLTSCR1, and SMARCA4 ChIP-seq experiments.\
b. Heatmap representing correlations between normalized ChIP-seq reads (Log2(RPM)) over a merged set of all mSWI/SNF subunit peaks. ChIP performed in n=2 independent samples for each.\
c. Localization of ncBAF, BAF, and PBAF complexes at the *VEGFA* locus. ChIP performed in n=2 independent samples for each.\
d. Heatmap of CentriMo log adjusted p-values for top motifs returned by MEME-ChIP analysis for each ChIP-seq experiment. ChIP performed in n=2 independent samples for each, p-values were calculated using binomial test.\
e. Proportion of peaks from ChIP-seq experiments using indicated antibodies overlapping CTCF ChIP-seq peaks in MOLM-13 and EoL-1 cell lines.\
f. Pie graphs reflecting proportion of ncBAF-, BAF-, and PBAF- specific peaks overlapping with specified chromatin features (see also [Supplementary Fig. 2i](#SD1){ref-type="supplementary-material"}).\
g. Example tracks demonstrating differential mSWI/SNF complex family enrichment across the *AFTPH* locus.\
ChIP performed in n=2 independent samples for each.](nihms-1507828-f0002){#F2}

![ncBAF components are selective synthetic lethal dependencies in synovial sarcoma and rhabdoid tumor cell lines.\
a. Waterfall plots for CERES scores across n=393 cell lines screened using CRISPR-Cas9 (Project Achilles). SS (orange) and MRT (blue) cell lines are indicated. Dashed line represents median dependency.\
b. BRD9 sensitivity across n=387 cell lines in Project DRIVE. Two-sided Fisher's exact test -log10(pvalue) for BRD9 sensitivity (ATARIS score\<-.75) against median z-score in each cancer type. Annotations with FDR\<0.1 are colored in red.\
c. Heatmap of CERES scores in SYO-1 (SS18-SSX-driven SS) and SW982 (histological SS mimic without SS18-SSX translocation) ranked by difference in dependency.\
d. (Top) Immunoblot on total cell lysates from SYO-1 cells in each knockdown condition (n=2 biologically independent experiments); (Bottom) Proliferation experiments in SYO-1 representative of n=3 biologically-independent experiments (with separate lentiviral infection and cell number calculations) performed. Each data point represents mean +/- SD, p-value calculated by two-sided t-test on day 19. See also [Supplementary Figure 7c](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.\
e. (Left) Chemical structure of dBRD9 degron compound; (Right) Immunoblot on total cell lysates from SYO-1 cells treated with DMSO vehicle control or dBRD9 (500nM) for 3 days (n=2 biologically independent experiments). See also [Supplementary Figure 7d](#SD1){ref-type="supplementary-material"}.\
f. Proliferation experiments in SYO-1 representative of n=3 biologically-independent experiments (separate treatments and cell number calculations). Each data point represents mean +/- SD, p-value calculated by two-sided t-test on day 8. See also [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.\
g. Heatmap of gene expression changes of significantly changed genes (p-adjusted\<.001 and log2(fc)\>.59; Benjamini-Hochberg) in any one of the four treatments. Genes were k-means clustered into 2 groups, samples were clustered hierarchically. n=2 biological replicates for each RNA-seq experiment.\
h. (Top) Immunoblot on total cell lysates from TTC1240 malignant rhabdoid tumor cells treated with either DMSO vehicle control or dBRD9 (250nM) (n=2 biologically independent experiments); (Bottom) Proliferation experiments in TTC1240 representative of n=3 biologically-independent experiments (separate treatments and cell number calculations). Each data point represents mean +/- SD, p-value calculated by two-sided t-test on day 7. See also [Supplementary Figure 7e](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.\
i. Representative colony formation assay performed on SYO-1 cells treated with dBRD9, BI-7273, or lenalidomide as a control (n=3 biologically independent experiments).](nihms-1507828-f0003){#F3}

![ncBAF subunit domains underlie complex-specific synthetic lethalities.\
a. Schematic for tiled gRNA CRISPR-Cas9 screening performed across mSWI/SNF subunit genes in SYO-1 SS cells.\
b. Tiled CRISPR screening for the *GLTSCR1* gene in SYO-1 cells.\
c,d. Tiled CRISPR screening for the *BRD9* gene (c) and *BRD7* gene (d) in SYO-1 cells.\
e. Alignment of GLTSCR1 amino acid sequences across species. GLTSCR domain is highlighted.\
f. Alignment of amino acid sequences for BRD9 and BRD7 across species. Bromodomain and DUF3512 are highlighted.\
g. (Top) Construct design for GLTSCR domain experiments in HEK-293T cells. (Bottom) Immunoprecipitation of V5-tagged constructs followed by immunoblot (n=2 biologically independent experiments). See also [Supplementary Figure 7f](#SD1){ref-type="supplementary-material"}.\
h. (Left) Construct design for C-terminal swap experiments for BRD9 and BRD7 in HEK-293T cells (BD = bromodomain). (Right) Immunoprecipitation of BRD9, BRD7, and BRD7(B9C) and BRD9(B7C) C-terminal swap variants followed by immunoblot in HEK-293T cells (n=2 biologically independent experiments). See also [Supplementary Figure 7g](#SD1){ref-type="supplementary-material"}.](nihms-1507828-f0004){#F4}

![ncBAF is not required for SS18-SSX1-mediated gene expression and primarily regulates fusion-independent sites.\
a. Immunoblot for ncBAF components in HA-SS18 and HA-SS18-SSX complex purifications (n=1 biologically independent experiment). See also [Supplementary Figure 7h](#SD1){ref-type="supplementary-material"}.\
b. Heatmap of significantly downregulated genes (p-adjusted\<1e-3 and log2(fold change)\< -0.59) in shSS18-SSX (7 days post infection) and dBRD9 (3 and 6 days) conditions in SYO-1 cells k-means clustered into 4 groups. n=2 biological replicates for each RNA-seq experiment, p-adjusted values are Benjamini-Hochberg adjusted Wald p-values.\
c. GSEA of RNA-seq data for shSS18-SSX and dBRD9 (day 6) conditions in (b). Specific pathways and gene sets are indicated.\
d. (Top) Immunoblot on CRL7250 whole cell lysates described in [Figure S5B](#SD1){ref-type="supplementary-material"} (n=1 biologically independent experiment); (Bottom) Heatmap of log2(fold change) of gene expression in CRL7250 fibroblast cells treated with DMSO, dBRD9, or dBRD9 followed by lentiviral introduction of V5-SS18 or V5-SS18-SSX (n=2 biological replicates for each RNA-seq experiment). Genes included were expressed (\>1 RPKM) and had a log2(fold change) of at least +/-.59 in at least one of the conditions. Genes were k-means clustered into 2 groups and samples were clustered hierarchically. See also [Supplementary Figure 7i](#SD1){ref-type="supplementary-material"}.\
e. Heatmap of ChIP-seq read density of SS18, BRD9, and H3K4me3 over SS18 sites in SYO-1 cells (shScr (control hairpin) and shSSX (targeting SS18-SSX) conditions), clustered into 3 groups.\
f. Box plot of log2(fold change) in gene expression of genes closest to fusion-dependent sites (n=595) in shSS18-SSX and dBRD9 conditions. n=2 independent samples for each ChIP performed, significance was calculated by two tailed t-test. Box represents interquartile range (IQR), bar in center shows data median. Minima and maxima shown extend to from the box +/- 1.5\*IQR.\
g. Pie chart representing chromatin landscape (fusion-dependent, fusion-independent promoter, fusion-independent distal) of the nearest BRD9 peak to the top 500 most downregulated genes.\
h. Violin plot of CERES scores for genes that changed with a significance of p-adjusted\<1e-3 after 6 days of dBRD9 treatment in SYO-1 cells. P-value between conditions calculated by two tailed t-test. Violin plot represents kernel density estimation with data quartiles represented as lines, the data median is shown as a dot.](nihms-1507828-f0005){#F5}

![ncBAF is required for maintenance of gene expression and retains co-localization with promoters and CTCF in SMARCB1-deficient cancers.\
a. Venn diagram of BRD9 and SMARCA4 ChIP-seq peaks in TTC1240.\
b. Bar plot of proportion of SMARCA4 peaks that overlap with a BRD9 peak in SS, MRT and mSWI/SNF-intact hematopoietic cancer cell lines. n=2 independent ChIPs, p-value calculated with two tailed t-test.\
c. Proportion of MRT-specific super-enhancers (SE) (Chun et al.) overlapping a BRD9 peak in TTC1240.\
d. log2(fold change) in SMARCA4 occupancy against mean occupancy between DMSO and dBRD9 treated TTC1240 cells. Highlighted, occupancy change of FDR\<5e-2. n=2 biological replicates per ChIP, FDR values are multiple test corrected Wilcox test p-values.\
e. Tracks showing BRD9, H3K27ac, and SMARCA4 +DMSO and +dBRD9 occupancy in TTC1240 at *SPARCL1* (n=2 independent samples for each ChIP performed).\
f. Spike-in normalized heatmap of SMARCA4 and BRD9 ChIP occupancy across lost SMARCA4 sites in TTC1240 upon dBRD9 treatment ranked by SMARCA4 occupancy in DMSO condition.\
g. Boxplot of H3K27ac ChIP occupancy in TTC1240 cells at SMARCA4 sites lost or retained upon dBRD9 treatment. Box represents interquartile range (IQR), bar in center shows data median. Minima and maxima shown extend to from the box +/- 1.5\*IQR with data falling outside of that range shown as points.\
h. Volcano plot of gene expression changes in TTC1240 with dBRD9 treatment (7 days). Blue indicates genes with TSS within 100kb of a lost site. MRT disease-associated genes (Chun et al.) with TSS\<100kb from peak are labeled. n=2 biological replicates for each RNA-seq experiment, p-adjusted values are Benjamini-Hochberg adjusted Wald p-values.\
i. Histograms of log2(fold change) in SMARCA4 ChIP occupancy across SMARCA4 peaks in TTC1240 and MOLM-13 after dBRD9 treatment.\
j,k. SMARCA4 (j) and BRD9 (k) peak distribution in BAF-perturbed (TTC1240 and SYO-1) and BAF-wild-type (EoL-1, MOLM-13, Jurkat) settings.\
l, m. Model for ncBAF dependency in cancers driven by cBAF perturbations. Perturbations in the core BAF functional module (SMARCB1, SMARCE1, ARID1A/B, with the exception of the ATPase subunits) result in loss of cBAF gene regulatory function and reliance on ncBAF for gene expression maintenance at hallmark ncBAF promoters and CTCF sites (l). Chemical or biologic ncBAF disruption results in loss of gene expression maintenance (m).](nihms-1507828-f0006){#F6}
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